 But the issue is that the vaccine, remember this is going to be a medication that we plan to inoculate into two, three hundred million people in this country, not to mention globally, we need absolute reassurance that this medication, this vaccine, has undergone all the appropriate phases of clinical trials in terms of safety and efficacy. And so as you probably know, the vaccines that are undergoing clinical trials right now, phase three, that's that phase where it's testing not only a large number of people thirty, forty thousand, but it's not just the number, but it's the timeline. It's monitoring for possible potential adverse events. We're trying to do this for this novel disease in less than a year. It makes a lot of us quite skeptical, Katie.